通过TGF-β1 / MAPK信号通路,HBI-8000通过保存的射出分数改善心力衰竭
Jing Tian1, Wenjing Li1, Lu Zeng2
1Central Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China.
Journal of cellular and molecular medicine
|March 21, 2024
概括
奇达胺 (HBI-8000) 显示出治疗心力衰竭的前景,使用保存的喷射分数 (HFpEF). 这项研究发现,HBI-8000通过调节TGF-β1 / MAPK通路来抑制心脏纤维化和缩,为HFpEF患者提供了新的希望.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 分子生物学分子生物学
背景情况:
- 保存喷射分数 (HFpEF) 的心力衰竭影响50%的心力衰竭患者,呈现心脏重塑和并发症.
- 对于HFpEF,有效的治疗选择有限,这凸显了对新型治疗策略的需求.
- 基达胺 (HBI-8000) 是一种基脱乙酶抑制剂,已被批准用于T细胞淋巴瘤,但在心血管疾病中显示出潜力.
研究的目的:
- 调查奇达胺 (HBI-8000) 的治疗潜力,以保存的喷射分数 (HFpEF) 治疗心力衰竭.
- 在HFpEF模型中阐明HBI-8000影响心肌纤维化和心肌缩的细胞机制.
主要方法:
- 在使用HFpEF模型的体内研究.
- 细胞测试检查HBI-8000对心脏纤维细胞 (CF) 和TGF-β1/MAPK通路的影响.
- 纤维化相关因素和酸化MAPK的分析 (p38MAPK,JNK,ERK).
主要成果:
- HBI-8000抑制了心脏纤维细胞的AngII诱导的增殖和激活.
- 在HFpEF模型中,HBI-8000降低了与纤维化相关的因素,并显著降低了TGF-β1和酸化MAPK的表达.
- 药物的作用与调节TGF-β1 / MAPK通路有关,这是纤维细胞重塑的关键驱动因素.
结论:
- 奇胺 (HBI-8000) 证明在抑制心肌纤维化和高缩方面具有有效性.
- 调节TGF-β1/MAPK通路是HBI-8000在HFpEF治疗效果的基础机制.
- HBI-8000代表了一种潜在的新型治疗药物,用于心力衰竭患者,其喷射分数被保存.
相关概念视频
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
428
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
428
01:17Pathophysiology of Heart Failure
1.6K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.6K
01:22Heart Failure Drugs: β-Blockers
338
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
338